BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+25.41%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$16.7B
AUM Growth
+$16.7B
(+9.1%)
Cap. Flow
-$302M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$39.8M |
| 2 |
Prime Medicine
PRME
|
$19.1M |
| 3 |
Replimune Group
REPL
|
$18.6M |
| 4 |
ARS Pharmaceuticals
SPRY
|
$17.1M |
| 5 |
Denali Therapeutics
DNLI
|
$13.9M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$254M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$92.6M |
| 3 |
Travere Therapeutics
TVTX
|
$43.6M |
| 4 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$37.6M |
| 5 |
Altimmune
ALT
|
$18.4M |
Sector Composition
| 1 | Healthcare | 99.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Alkermes
ALKS
$4.95B
| – | – |
-815,016
| Closed | -$18.2M |
|